British pharmaceutical group GSK sees strong commercial potential for one of its experimental cancer treatments after the publication of encouraging initial data. The drug, called "Morez," has shown significant effects in reducing tumors in patients with advanced and difficult-to-treat cancers.
According to preliminary results presented at a medical conference in Puerto Rico, the treatment led to a significant reduction in tumor size, defined as a decrease of at least 30% in a substantial proportion of patients. In cases of ovarian cancer resistant to platinum-based treatments, 62% of patients reached this threshold, compared to 67% for those with endometrial cancer.
“This is one of our top priorities at this stage,” said Hesham Abdullah, head of oncology research at GSK, during a press briefing. When asked about the treatment’s potential, he didn’t hesitate to suggest a possible “resounding success,” highlighting the high hopes placed in this targeted therapy.
These results, although preliminary, could strengthen GSK's position in the field of oncology, a strategic sector for the pharmaceutical industry. The company now plans to continue developing the drug through five late-stage clinical trials, a crucial step before potential market launch.
Analysts have not yet provided sales estimates due to the early stage of data. However, these scientific advances offer a new impetus to the group's oncology business, in a context of increased competition for the development of innovative treatments against the most resistant cancers.
Community
Comments
Comments are open, but protected against spam. Initial posts and comments containing links undergo manual review.
Be the first to comment on this article.